Brought to you by 
Esprit Pharma gets rights to Depomed's Proquin for $50mm
05 Jul 2007
Executive Summary
Esprit Pharma (in-licenses urology drugs) has licensed exclusive US / Puerto Rican marketing and distribution rights to Depomed's recently approved extended-release formulation of Proquin (ciprofloxacin) for simple urinary tract infections.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Esprit Pharma gets rights to Depomed's Proquin for $50mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice